TransCode Therapeutics, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Over-allotment Option
BOSTON–(BUSINESS WIRE)–TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics,…
